AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025 after the CVS GLP-1 formulary change. In contrast, AOM semaglutide increased by +0.1 points...
What happens to cardiovascular health when patients stop taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications? That’s the focus of new research from investigators at Baylor Scott & White Research Institute and Stony Brook University Hospital,...
Biomarker testing has transformed cancer care over the past decade, opening the door to targeted therapies that can improve outcomes for patients with advanced disease. Yet despite strong guideline recommendations, many patients with metastatic non-small cell lung...
Multiple sclerosis (MS) affects approximately 1 million people in the United States, with women representing nearly 75% of patients. Over the past decade, consensus guidelines from leading MS experts have increasingly emphasized the importance of early intervention...
After years of uncertainty, a recent policy change is sparking new optimism in rare disease drug development. A change in federal policy now keeps certain multi-indication rare therapies exempt from Medicare price negotiations—a rule that had discouraged some...
In this edition of Truveta experts, Esther Kim, PhD, MPH, Senior Director of Research Services at Truveta, shares findings from her recent exploration of the burden of sudden cardiac arrest (SCA) or sudden cardiac death (SCD), as well as cardiac arrhythmias, among...
Why do patients stop taking a medication? Was it due to side effects, access barriers, or lack of efficacy? These are not just clinical questions; they’re strategic ones. Understanding treatment discontinuation is essential for improving therapy design, informing...
62.7% of Lyme cases occurred between May and August, underscoring the heightened risk during late spring and summer. June consistently showed the highest activity, accounting for nearly 1 in 5 cases (19.4%) across observed years. Risk of Lyme remains elevated in...
